Adherent cells from HIV-infected subjects as well as in vitro HIV-infected normal adherent cells produce spontaneously a 29-kD (p29) factor that inhibits mitogen-induced proliferation of normal T cells. p29 mediates a partial dose-dependent inhibition of total protein synthesis in both nonstimulated and PHAactivated cells that is associated with impaired PHA-induced expression ofIL-2 receptor (IL-2R)a chain, HLA-class II molecules, and production of IL-2 by these cells; conversely, p29 does not modify the expression of IL-2RB chain, 4F2, CD9, or transferrin receptor, or the production of IL-1 and TNFa by the cells. 1 h preincubation of the cells with p29 is sufficient to detect its biologic activity and added rIL-2 abrogates p29-induced inhibition of IL-2Ra chain expression; however, p29 does not display any biologic effect on already expressed IL2Ra chains. The impaired expression of IL-2Ra chain mediated by p29 is not due to a decreased accumulation of the corresponding mRNA transcripts, but is associated with a twofold increase of intracellular cAMP. Binding experiments with '251-rIL-2 reveals that p29 induces a 50% decrease in the number of both high and low affinity IL-2R per cell. p29 also inhibits alloantigen-induced proliferation of PBMC, whereas it does not modify IL-2-dependent proliferation of 48-h PHAblasts that already express high affinity IL-2R. These findings indicate that p29 mediates its biologic activity during early stages of T cell activation affecting the expression of high affinity IL-2R and production of IL-2, through a nontranscriptional mechanism involving an increase of intracellular cAMP. (J.
Introduction
Antigens or mitogens activate normal T cells which then ex- press different novel molecules on their surface, such as IL-2 receptors (IL-2R),' CD9, CD69, 4F2, HLA-class II molecules (1) (2) (3) and produce a number of cytokines such as IL-2, IL-4, -IFN, etc., (4) which participate in cell cooperation. Cell activa-tion is followed by cell proliferation which is regulated by the binding of IL-2 to its high affinity functional IL-2R (5) (6) .
Functional IL-2R has been shown to be composed of, at least, two different IL-2-binding chains: IL-2Ra chain (also named Tac molecule or p55) binds its ligant with a low affinity (Kd = 10-12 M) (7) and IL-2R# (also named p75) which binds IL-2 with an intermediate affinity (Kd = 0.2-1 X 10`0 M) (8) (9) (10) . The association of these chains is needed to form high affinity IL-2R (1 1-13). Monoclonal antibodies have been developed against these already isolated IL-2-binding polypeptides and their genes have been cloned and sequenced (14) (15) (16) (17) .
Infection by HIV is followed by severe impairment of cellmediated immune responses that can be detected at all clinical stages ofthe disease (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . These abnormalities could be due to the decreased number of CD4' cells since these cells have a key role in both cell-mediated and humoral immunity against various antigens. Moreover, CD4' cells display various functional abnormalities which seem to be due to several mechanisms. Indeed , it has been reported that viral envelope protein gp 120 can mediate an immunosuppressive effect on T cell responses, probably through impaired signal transduction (28) (29) (30) (31) . Moreover, HIV-infected cells can produce factors that inhibit normal T cell activation (32, 33) or IL-1 activity (34, 35) .
We recently reported that adherent cells from HIV-infected subjects spontaneously produce an activity inhibiting the in vitro clonal proliferation of T cells from both patients and normal subjects through decreased production of IL-2 and expression of IL-2Ra chain (36). This inhibitory activity, which is also produced after in vitro HIV infection of normal adherent cells, was shown to be due to a thermosensible protein of29 kD (p29) partially purified by chromatography, SDS-PAGE, and elution of the proteins from the gel (37) . p29 is distinct from viral p24, gpl 20 , and nef proteins as well as from a/f-and interferons, prostaglandin E2, tumor necrosis factor a, and transforming growth factor ( (37) . p29 could not be detected in media conditioned by adherent cells from normal HIV seronegative subjects and patients with other various viral, parasitic, or fungal diseases suggesting that secretion of this inhibitory factor is associated with HIV infection (37) .
The cellular origin of p29 seems to indicate that this molecule could be involved in the regulation of normal immune response through modulation ofthe IL-2/IL-2R system. Thus, we investigated the effect of p29 on cell activation and, more precisely, on the IL-2R function. Our findings demonstrate that p29 can inhibit the expression of IL-2Ra, but not IL-2Rf3 chain, inducing a decrease in number of both high and low affinity receptors per cell. In addition, p29 decreases IL-2 production by normal T cells, thus leading to an inhibition of normal cell proliferation. These modifications of T cell growth are associated with a p29-mediated increase of intracellular cAMP accumulation that has recently been shown to modulate the expression of IL-2R chains (38) (39) .
Methods
Cells. PBMC were obtained from healthy blood donors by FicollPaque (Pharmacia Fine Chemicals, Uppsala, Sweden) density (d = 1,077 g/liter) centrifugation of heparinized blood. Interface cells were resuspended in RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (Gibco), 2 mM L-glutamine and antibiotics (1% vol/vol) (complete growth medium) at 106 cells/ml. Cells were activated for 48 h with PHA-P (0.1% vol/vol; Difco Laboratories Inc., Detroit, MI) (PHAblasts) in the presence or the absence of p29 (0.25 pig/ml), which was biochemically partially purified by G25, gel filtration, and anion-exchange chromatography as reported previously (37) Binding of "2SI-recombinant IL-2 (rIL-2). PBMC stimulated as above in the presence or the absence of partially purified p29 (0.25 ,g/ml) for 48 h, were washed twice, incubated for 1 h in complete growth medium at 37°C, washed again, and counted. Binding of '25I-rIL-2 was performed according to Robb et al. (7) with slight modifications (40 [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Ci/mmol; CEA) for an additional 16 h. Cells were recovered using a cell harvester and cell-associated radioactivity was counted by liquid scintillation. In some experiments, 48-h PHA-blasts were used to determine the effect of p29 on the IL-2-induced cell proliferation. For this purpose, washed cells were incubated in the presence of increasing concentrations of rIL-2 (Eurocetus; Emeryville, The Netherlands) in the absence or the presence of p29 (0.25 Mg/ml). After a 48-h cell incubation, cell proliferation was determined by [3H]thymidine incorporation as above.
IL-2 assa'. IL-2 activity in media conditioned by PHA-activated cells in the presence of p29 was determined using cytotoxic T lymphocyte line (CTLL)-2 cells according to the method described by Mosman (41) as modified by Tada (42) . Briefly, 50 Ml of twofold dilutions of the supernatant to be tested were added per well in 96 flat-bottomed microplates. Then, 6 x 103 CTLL-2 cells, resuspended in complete growth medium supplemented with 1 0`M 2-mercaptoethanol, were added to each microwell. Microplates were incubated at 37°C in 5% CO2 in air for 24 h and viable proliferating cells were detected by adding 20 Ml/well of bromure 3-(4,5 dimethylthiazol)-2,5-diphenyltetrazolium (MTT; Sigma Chemical Co.). 100 Ml of 10% SDS-HCl 0.01 M were added for an additional 4-6 h. Controls included twofold dilutions of 25 French U/ml rIL-2 (1 French unit of IL-2 = 40 Biological Response Modifying Program units), complete growth medium, and complete growth medium supplemented with twofold dilutions of rIL-2. Absorbance was monitored at 570 nm. Dosage of tumor necrosis factor a (TNFa) and ILI. Production of TNFa by activated PBMC was determined in conditioned media using a commercial immunoenzymatic assay (Biokine; T-cell Sciences, Inc., Cambridge, MA) according to the manufacturer's instructions. IL-1 activity in the same conditioned media was determined using the IL-1 -dependent D1O.G4 murine cell line. For this purpose, D1O.G4 cells were washed, incubated in complete serum-free growth medium for 1 h at 37°C, washed again and seeded (104 cells/ml) in flat-bottomed microplates in the presence of twofold dilutions of 25 U/ml human rIL-1 (Boehringer Mannheim GmbH, Mannheim, FRG) or in the presence of similar dilutions of the supernatant to be tested. Additional controls were included as described for IL-2 dosage. Cultures were incubated for 48 h and pulsed with 1 Ci/well [3H]thymidine for an additional 16 h.
Cell-associated radioactivity was measured by liquid scintillation.
Results
Effect of p29 on protein synthesis. We initially investigated whether p29 can inhibit the overall protein synthesis by PHA- Effect ofp29 on the expression ofactivation-associated molecules. Since p29 mediates a partial inhibition ofprotein synthesis, it was ofinterest to investigate whether this factor displays a specific effect on the expression of different molecules or the production of various cytokines produced during cell activation. Fig. 1 demonstrates that p29 could inhibit the expression ofIL2-Ra (p55) but not ofIL-2R,3 (p70) chains. It is interesting to note that the biphasic pattern of p29-mediated effect on the expression of IL-2Ra chain (Fig. 1) suggests that p29-mediated inhibitory activity is confined to a subpopulation of PBMC. Moreover, p29 induced an inhibition of HLA class-II molecules expression (Table II) . Conversely, p29 did not modulate the expression oftransferrin receptor, 4F2 and CD9 molecules. 1 h preincubation of normal PBMC with p29 at 37°C was sufficient to mediate its biologic activity (Table III) whereas incubation of 48-h PHA-blasts with this factor did not modulate IL-2Ra chain expression on these cells (Table III) . Exogenously added rIL-2 abrogated the inhibitory effect of p29 on the IL-2Ra chain expression in a dose-dependent manner (Fig. 2) . In parallel experiments we studied the production of some cytokines by cells stimulated in the presence of p29. Table IV shows that p29 inhibited by 50% the production of IL-2 whereas it did not inhibit the production ofIL-1 and TNFa; on the contrary, p29 slightly increased the secretion of these cytokines (Table 4) . p29 induces a decrease ofhigh and low affinity IL2-R/cell. Subsequently, we studied the affinity of IL-2R expressed on normal stimulated T cells cultured in the presence of p29. Fig.   3 indicates a representative experiment of 251I-rIL2 binding on these cells showing a twofold decrease of the number of high affinity IL-2-binding sites per cell (1,296 sites/cell) compared to cells stimulated in the absence of p29 (2,926 sites/cell). It should be noted that p29 increased the affinity of IL-2R in comparison to normal controls (Kd = 39 pM vs 190 pM, respectively; Fig. 3 ). In addition, Fig. 3 demonstrates that p29 also induced a decrease of the number of low affinity IL-2-binding sites per cell, which is known to correspond to membrane-expressed IL-2Ra molecules; this observation corroborates with the described p29-mediated decreased expression ofthis molecule. p29 cannot inhibit the accumulation ofIL2-Ra and IL2-R# mRNA. To investigate the mechanisms ofp29-induced inhibition of IL-2Ra chain expression, total RNA from cells incu- (Fig. 4) . Although the rehybridization ofthe same filters with a f3-actin cDNA probe revealed that there were some differences on the quantity of RNA loaded to the gels, the ratio of the unique band of 1.9 kb between the control and experimental points was the same, indicating that there is no significant effect of p29 on IL-2Ra mRNA accumulation. Fig. 5 also demonstrates that p29 has no effect on the accumulation of IL-2R, specific mRNA transcripts.
p29 induces the accumulation ofintracellular cAMP. cAMP has been reported to inhibit cell proliferation (43) (44) (45) and, recently, has been shown to posttranscriptionally modulate the expression ofboth IL-2-binding chains (38) (39) . Thus, we studied the effect of p29 on the accumulation of intracellular cAMP. Table V demonstrates higher content of intracellular cAMP than p29 (Table V) . This effect of p29 on the accumulation of intracellular cAMP was dose dependent reaching a plateau at relatively low concentrations of p29 (0.12 Atg/ml; not shown).
Effect ofp29 on cell proliferation. Since p29 inhibits both the expression of high IL-2R and IL-2 production by activated T cells we studied its effect on mitogen-and alloantigen-induced cell proliferation of normal cells. In several experiments performed p29 could not inhibit the proliferation of PHA-activated cells in a 72-h proliferation assay. Conversely, a clear inhibition of cell proliferation mediated by p29 could be detected in a 6-d assay. Indeed, Fig. 6 indicates an inhibition of cell proliferation in the presence of p29, irrespectively of the stimulus; however, it is noteworthy that inhibition was never more than 60% compared to control values. The addition of rIL-2 at the beginning ofthe culture could abrogate the inhibitory effect of p29 on PHA-induced cell proliferation (not shown), suggesting that p29-mediated inhibition ofcell proliferation is associated with the impaired production of IL2. In addition, p29 could not modify the IL-2-dependent proliferation of normal PHA-blasts (Table VI) .
Discussion
The results presented here demonstrate that p29 inhibitory factor, produced spontaneously by HIV-infected adherent cells (37) , partially inhibits the IL-2/IL-2-R system on mitogen-acti- Normal unfractionated PBMC (106/ml) were incubated in the presence or the absence of p29 (0.25 ,ug/ml) and PHA-P (0.1% vol/vol) or forskolin (2 ,uM/ml) for 15 min. Intracellular cAMP was determined by RIA as described in Methods. * Results are expressed as mean±SD values of intracellular cAMP (pg/ml) from five different experiments. (Fig. 3) . This IL-2Rf chain cDNA probes showed that p29 could not modify the accumulation of specific mRNA transcripts. Kinetic studies of IL-2Ra chain mRNA expression also showed the absence of a p29-mediated effect, suggesting that this finding is not due to a modified mRNA stability. The rehybridization of the filters with a f-actin cDNA probe demonstrated that the ratio ofintensity between control and experimental points was practically the same at all time points, we conclude that p29 does not modulate IL-2Ra chain expression at a transcriptional level. Taken together, these findings seem to indicate that p29 mediates its biological effect either at a translational level or/ and during the migration of normally synthesized proteins to the cell membrane. Moreover, our observations strongly suggest that the mechanisms controlling the expression of activation-associated molecules or the production of various cytokines present a differential sensitivity to p29. Whether this phenomenon is due to a differential sensitivity of the above mentioned mechanisms to p29-mediated accumulation of intracytoplasmic cAMP is an interesting question. Since 1-h cell preincubation with p29 was sufficient to detect its biologic activity and membrane expression of IL-2Ra chain is a relatively early event during T cell activation, appearing at -6-8 h after cell activation (5-6), it is reasonable to hypothesize that p29 biologic activity is mediated at some precocious stages of cell activation. Conversely, p29 could not modify IL-2-dependent cell proliferation of PHA-blasts suggesting that p29 did not possess an anti-IL-2 activity. These observations taken together with the p29-mediated increase of intracytoplasmic cAMP, strongly suggest that early accumulation of cAMP can prevent some cell functions important for cell activation.
Previous studies have shown that HIV infection of T cells induces an abnormal signal transduction and inhibition of IL2Ra gene expression (26, 29, 46, 47) . In our study, we demonstrated that p29 production by HIV-infected adherent cells, both in vivo and in vitro (36, 37), downregulates the expression of high affinity IL-2R through posttranscriptional impaired membrane expression of IL-2Ra chain. Thus, HIV-induced production of p29 protein should be an additional mechanism involved in the impaired proliferation capacity of T cells during HIV infection. Probably, these mechanisms act in synergy, thereby explaining the profound T cell functional abnormalities observed even at early stages of HIV infection when only a small percentage of T cells are expressing the virus.
